edotreotide has been researched along with Meningeal Neoplasms in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (60.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beliveau, V; Dudas, J; Gizewski, ER; Heugenhauser, J; Iglseder, A; Iglseder, S; Kerschbaumer, J; Nevinny-Stickel, M; Nowosielski, M; Scherfler, C; Stockhammer, G; Uprimny, C; Virgolini, I | 1 |
| Blau, T; Damman, P; Deuschl, C; Fendler, WP; Glas, M; Grueneisen, J; Guberina, M; Haubold, J; Kebir, S; Kessler, L; Li, Y; Milosevic, A; Morawitz, J; Schaarschmidt, BM; Styczen, H; Weber, M; Wrede, K | 1 |
| Combs, SE; Debus, J; Dittmar, A; Dittmar, JO; Giesel, FL; Haberkorn, U; Habermehl, D; Kratochwil, C; Rieken, S; Welzel, T | 1 |
| Aricò, D; Baio, SM; Bartolomei, M; Bodei, L; Botteri, E; Cremonesi, M; De Cicco, C; Grana, CM; Paganelli, G; Sansovini, M | 1 |
| Bamberg, M; Bares, R; Bartenstein, P; Belka, C; Eschmann, SM; Ganswindt, U; Gehler, B; Hauser, TK; Oksüz, MO; Paulsen, F; Pfannenberg, C | 1 |
| Beyer, T; Müller, AC; Pfannenberg, C; Thorwarth, D | 1 |
| Debus, J; Dimitrakopoulou-Strauss, A; Doll, J; Eisenhut, M; Haberkorn, U; Henze, M; Mäcke, HR; Milker-Zabel, S; Schuhmacher, J; Strauss, LG | 1 |
| Debus, J; Haberkorn, U; Henze, M; Hoess, A; Huber, P; Milker-Zabel, S; Schulz-Ertner, D; Zabel-du Bois, A | 1 |
| Becker, DW; Debus, J; Doll, J; Haberkorn, U; Henze, M; Hipp, P; Hofmann, M; Kowalski, J; Mäcke, HR; Schuhmacher, J | 1 |
| Bohuslavizki, KH | 1 |
2 trial(s) available for edotreotide and Meningeal Neoplasms
| Article | Year |
|---|---|
Peptide receptor radionuclide therapy with (90)Y-DOTATOC in recurrent meningioma.
Topics: Adolescent; Adult; Aged; Child; Female; Humans; Male; Meningeal Neoplasms; Meningioma; Middle Aged; Neoplasm Recurrence, Local; Octreotide; Radiopharmaceuticals; Receptors, Somatostatin; Young Adult; Yttrium Radioisotopes | 2009 |
Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas.
Topics: Adult; Aged; Aged, 80 and over; Brain; Female; Gallium Radioisotopes; Humans; Kinetics; Male; Meningeal Neoplasms; Meningioma; Metabolic Clearance Rate; Middle Aged; Octreotide; Organ Specificity; Positron-Emission Tomography; Radiopharmaceuticals | 2005 |
8 other study(ies) available for edotreotide and Meningeal Neoplasms
| Article | Year |
|---|---|
Somatostatin receptor subtype expression and radiomics from DWI-MRI represent SUV of [68Ga]Ga-DOTATOC PET in patients with meningioma.
Topics: Humans; Magnetic Resonance Imaging; Meningeal Neoplasms; Meningioma; Octreotide; Organometallic Compounds; Positron-Emission Tomography; Receptors, Somatostatin; Retrospective Studies | 2023 |
Correlation of the apparent diffusion coefficient with the standardized uptake value in meningioma of the skull plane using [68]Ga-DOTATOC PET/MRI.
Topics: Diffusion Magnetic Resonance Imaging; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Meningeal Neoplasms; Meningioma; Positron-Emission Tomography; Radiopharmaceuticals; Skull | 2023 |
First intraindividual comparison of contrast-enhanced MRI, FET- and DOTATOC- PET in patients with intracranial meningiomas.
Topics: Adult; Aged; Contrast Media; Female; Humans; Magnetic Resonance Imaging; Male; Meningeal Neoplasms; Meningioma; Middle Aged; Neuroimaging; Octreotide; Positron-Emission Tomography; Radiopharmaceuticals; Tyrosine | 2017 |
[68Ga]-DOTATOC-PET/CT for meningioma IMRT treatment planning.
Topics: Adult; Aged; Aged, 80 and over; Female; Gallium Radioisotopes; Humans; Magnetic Resonance Imaging; Male; Meningeal Neoplasms; Meningioma; Middle Aged; Octreotide; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated; Tomography, X-Ray Computed | 2009 |
Combined PET/MR imaging using (68)Ga-DOTATOC for radiotherapy treatment planning in meningioma patients.
Topics: Aged; Female; Gallium Radioisotopes; Humans; Magnetic Resonance Imaging; Meningeal Neoplasms; Meningioma; Octreotide; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted | 2013 |
Improved target volume definition for fractionated stereotactic radiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and [68Ga]-DOTATOC-PET.
Topics: Adult; Aged; Female; Humans; Magnetic Resonance Imaging; Male; Meningeal Neoplasms; Meningioma; Middle Aged; Neoplasm Recurrence, Local; Octreotide; Positron-Emission Tomography; Radiopharmaceuticals; Radiosurgery; Receptors, Somatostatin; Tomography, X-Ray Computed | 2006 |
PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas.
Topics: Gallium Radioisotopes; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Meningeal Neoplasms; Meningioma; Octreotide; Pilot Projects; Radiopharmaceuticals; Receptors, Somatostatin; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed | 2001 |
Somatostatin receptor imaging: current status and future perspectives.
Topics: Gallium Radioisotopes; Humans; Indium Radioisotopes; Meningeal Neoplasms; Meningioma; Octreotide; Pentetic Acid; Radiopharmaceuticals; Receptors, Somatostatin; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon | 2001 |